Literature DB >> 17168834

Will diverse Tat interactions lead to novel antiretroviral drug targets?

David Harrich1, Nigel McMillan, Liliana Munoz, Ann Apolloni, Luke Meredith.   

Abstract

More than fifteen years following the description of Tat as a critical HIV gene expression regulatory protein, additional roles for Tat in HIV replication have been described, including reverse transcription. Tat achieves function through direct interaction with viral proteins, including reverse transcriptase, and numerous cellular proteins including cyclin T1, RNA polymerase II, protein kinase R (PKR), p300/CBP, and P/CAF. Despite our advanced knowledge of how Tat operates, this has not yet resulted in the discovery of effective agents capable of targeting various Tat functions. Nevertheless, Tat remains an attractive, virus-specific molecule and detailed understanding of specific protein interaction holds promise for future drug discovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17168834     DOI: 10.2174/138945006779025338

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  3 in total

1.  In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat.

Authors:  Stephen E Braun; Ran Taube; Quan Zhu; Fay Eng Wong; Akikazu Murakami; Erick Kamau; Markryan Dwyer; Gang Qiu; Janet Daigle; Angela Carville; R Paul Johnson; Wayne A Marasco
Journal:  Hum Gene Ther       Date:  2012-09       Impact factor: 5.695

2.  Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages.

Authors:  Wen Kang; Wayne A Marasco; Hsin-I Tong; Mary Margaret Byron; Chengxiang Wu; Yingli Shi; Si Sun; Yongtao Sun; Yuanan Lu
Journal:  J Neuroinflammation       Date:  2014-11-22       Impact factor: 8.322

3.  Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant.

Authors:  Hongping Jin; Yifan Sun; Dongsheng Li; Min-Hsuan Lin; Mary Lor; Lina Rustanti; David Harrich
Journal:  mBio       Date:  2019-08-27       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.